Certolizumab pegol

被引：47

作者：

Melmed, Gil Y. ^{[1
]}

Targan, Stephan R. ^{[1
]}

Yasothan, Uma ^{[2
]}

Hanicq, Delphine ^{[2
]}

Kirkpatrick, Peter

机构：

[1] Univ Calif Los Angeles, Sch Med, Cedars Sinai Inflammatory Bowel Dis Ctr, Los Angeles, CA 90048 USA

[2] IMS Hlth, London NW1 6JB, England

来源：

NATURE REVIEWS DRUG DISCOVERY | 2008年 / 7卷 / 08期

关键词：

D O I：

10.1038/nrd2654

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

[No abstract available]

引用

页码：641 / 642

页数：2

共 14 条

[1] The immunological and genetic basis of inflammatory bowel disease [J].

Bouma, G ;

Strober, W .

NATURE REVIEWS IMMUNOLOGY, 2003, 3 (07) :521-533

[2]

CHANG JT, 2006, HEPATOLOGY, V3, P220

[3] Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial [J].

Colombel, Jean-Frederic ;

Sandborn, William J. ;

Rutgeerts, Paul ;

Enns, Robert ;

Hanauer, Stephen B. ;

Panaccione, Remo ;

Schreiber, Stefan ;

Byczkowski, Dan ;

Li, Ju ;

Kent, Jeffrey D. ;

Pollack, Paul F. .

GASTROENTEROLOGY, 2007, 132 (01) :52-65

[4] Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease:: an open randomised trial [J].

D'Haens, Geert ;

Baert, Filip ;

van Assche, Gert ;

Caenepeel, Philip ;

Vergauwe, Philippe ;

Tuynman, Hans ;

De Vos, Martine ;

van Deventer, Sander ;

Stitt, Larry ;

Donner, Allan ;

Vermeire, Severine ;

Van De Mierop, Frank J. ;

Coche, Jean-Charles R. ;

van der Woude, Janneke ;

Ochsenkuehn, Thomas ;

van Bodegraven, Ad A. ;

van Hootegem, Philippe P. ;

Lambrecht, Guy L. ;

Mana, Fazia ;

Rutgeerts, Paul ;

Feagan, Brian G. ;

Hommes, Daniel .

LANCET, 2008, 371 (9613) :660-667

[5]

*FDA, 2008, FDA LAB INF

[6]

*IMS, 2007, IMS HLTH AN IMS MIDA

[7] Evolving knowledge and therapy of inflammatory bowel disease [J].

Korzenik, JR ;

Podolsky, DK .

NATURE REVIEWS DRUG DISCOVERY, 2006, 5 (03) :197-209

[8] Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences [J].

Loftus, EV .

GASTROENTEROLOGY, 2004, 126 (06) :1504-1517

[9] Mechanism of action of certolizumab pegol (CDP870): In vitro comparison with other anti-tumor necrosis factor at agents [J].

Nesbitt, Andrew ;

Fossati, Gianluca ;

Bergin, Marianne ;

Stephens, Paul ;

Stephens, Sue ;

Foulkes, Roly ;

Brown, Derek ;

Robinson, Martyn ;

Bourne, Tim .

INFLAMMATORY BOWEL DISEASES, 2007, 13 (11) :1323-1332

[10]

PEYRINBIROULET L, 2008, HEPATOLOGY, V6, P644

← 1 2 →